RBBP8 and urinary bladder carcinoma: Hence, we provide a novel biomarker candidate, i.e., RBBP8, which has previously been shown to sensitize tumor cells for PARP1 inhibitors and which may improve entity-specificity for monitoring, early detection, and clinical management of bladder cancer in a urine biomarker panel.